February 01, 2026 a 03:43 pm
TECH: Fundamental Ratio Analysis - Bio-Techne Corporation
Bio-Techne Corporation is a diversified player in the biotechnology sector, offering life science reagents and diagnostic tools worldwide. With a strong presence in both research and clinical diagnostics, the company captivates investors through innovation in genomics and proteomics. However, potential investors should be mindful of sector dynamics and competition.
Fundamental Rating
The current fundamentals of Bio-Techne Corporation indicate a moderate outlook, with some strengths in discounted cash flow and equity returns.
| Category | Score | Visualization |
|---|---|---|
| Overall | 2 | |
| Discounted Cash Flow | 3 | |
| Return on Equity | 3 | |
| Return on Assets | 3 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
Historical data reflects a consistent performance in most areas, with stability in their scoring metrics over the recent past.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-30 | 2 | 3 | 3 | 3 | 2 | 1 | 2 |
| No Specific Date | 0 | 3 | 3 | 3 | 2 | 1 | 2 |
Analyst Price Targets
Analyst estimates forecast a positive trend for Bio-Techne, with consensus for a "Buy" in the upcoming periods.
| High | Low | Median | Consensus |
|---|---|---|---|
| $73 | $62 | $70 | $68.75 |
Analyst Sentiment
The market sentiment suggests a promising outlook, primarily supported by multiple buy recommendations.
| Rating | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Bio-Techne Corporation offers a balanced investment outlook with solid fundamentals in areas important for future growth. The company's diverse product line underpins its market stability and potential for higher valuations. Analysts are optimistic, suggesting further buy opportunities, although price volatility and sector competition could present risks. Therefore, closely monitoring market conditions and competitor activities remains essential for stakeholders.